Total Voting Rights

Summary by AI BETAClose X

Dr. Martens plc has announced its total voting rights as of September 30, 2026, stating that its issued ordinary share capital comprises 968,026,973 ordinary shares, each with one voting right, and no shares are held in treasury. This figure of 968,026,973 represents the total number of shares with voting rights and serves as the denominator for shareholders calculating their notification obligations under the FCA's Disclosure Guidance and Transparency Rules.

Disclaimer*

Dr. Martens PLC
30 September 2026
 

Dr. Martens plc (the "Company")

 

Total Voting Rights

 

The following information is released in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1.

 

As at the date of this disclosure, the Company's issued ordinary share capital consists of 968,026,973 ordinary shares of GBP 0.01 each, each carrying one voting right. The Company does not hold any shares in Treasury. Therefore, the total number of shares with voting rights in the Company is 968,026,973.

 

The above figure (968,026,973) can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 

 

For further information please contact:

 

Zhwan Woof

Company Secretarial

Dr. Martens plc

+44 75853982165

 

ABOUT DR. MARTENS

 

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1 April 1960. Stitched into its heel loop were three words in the founder's own handwriting, a nod to the boot's new air-cushioned sole: With Bouncing Soles. Originally chosen by workers for their comfort and durability, "Doc's" or "DM's" boots and shoes were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

 

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques.

 

Those same three words are now the brand's enduring global platform. With Bouncing Soles is not a tagline or a seasonal campaign; it is a statement of intent and a creative thread that runs through everything Dr. Martens does, from product and retail to partnerships and community. What began as a promise of comfort has become an opportunity for reflection and a call to action: What Makes Your Sole Bounce? 

 

It celebrates the individuality, creativity and self-expression of a global community glorious in its differences, united by a yellow thread.

 

A brand built to put a bounce in the step of those who stand out from the crowd, Dr. Martens is available through Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels. The brand's collections span its original silhouettes, including The Icons such as the 1460 boot, 1461 shoe, 2976 Chelsea boot and Adrian loafer, as well as newer franchises including the Zebzag, Buzz and Lowell. The lineup also includes an extensive range of sandals, a dedicated Kids collection, and a curated selection of bags, small leather goods, and accessories. Every Dr. Martens collection reflects craftsmanship, heritage, timeless style, comfort, and versatility. Having transcended generations, the brand remains as relevant today as it was at its inception. Its signature yellow welt stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops remain iconic symbols recognised around the world.

 

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index.

 

For more information, visit www.drmartens.com or http://www.drmartensplc.com      

           

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Dr. Martens (DOCS)
UK 100